What is the drug donation policy for mobosetinib/mobosetinib?

Mobocertinib/ Mobocertinib is the first oral irreversible kinase inhibitor targeting EGFR and HER2 receptors; received Orphan Drug Designation on December 17, 2019 for the treatment of patients with non-small cell lung cancer with EGFR alterations, and subsequently received Breakthrough Therapy Designation and is commercially available in multiple countries.

This is the first oral drug approved to treat patients with locally advanced or metastatic non-small cell lung cancer who have EGFR exon 20 insertion mutations and whose disease has progressed during or after platinum-based chemotherapy. In clinical studies, the overall response rate (ORR) for disease that progressed during or after platinum-based chemotherapy was 28%, and the median duration of response was 17.5 months.

Due to its high price and cost of treatment, the financial burden can be a significant barrier to continued treatment for some patients. Therefore, many drug manufacturers, medical institutions and related organizations have launched drug donation policies to help patients with financial difficulties obtain the treatment they need.

Mobosetinib drug donation policy is usually led by pharmaceutical companies. Pharmaceutical companies set up special patient assistance programs designed to provide free drugs to patients who meet certain conditions. These conditions may include the patient's financial status, insurance coverage, and acceptance of other health insurance plans. Drug donation programs are especially important for patients who do not have insurance or have insufficient insurance to cover the cost of treatment.

Normally, patients need to fill out an application form and provide relevant supporting materials, such as income certificate, financial status statement, etc. Pharmaceutical companies review these applications to determine if the patient is eligible for the grant program. Patients can also seek assistance from their doctors during this process, who usually understand the drug donation policy and can provide guidance.